308 related articles for article (PubMed ID: 28404012)
1. A non-endoscopic device to sample the oesophageal microbiota: a case-control study.
Elliott DRF; Walker AW; O'Donovan M; Parkhill J; Fitzgerald RC
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):32-42. PubMed ID: 28404012
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.
Ross-Innes CS; Chettouh H; Achilleos A; Galeano-Dalmau N; Debiram-Beecham I; MacRae S; Fessas P; Walker E; Varghese S; Evan T; Lao-Sirieix PS; O'Donovan M; Malhotra S; Novelli M; Disep B; Kaye PV; Lovat LB; Haidry R; Griffin M; Ragunath K; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Ostler R; Aigret B; Sasieni PD; Fitzgerald RC;
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):23-31. PubMed ID: 28404010
[TBL] [Abstract][Full Text] [Related]
3. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
[TBL] [Abstract][Full Text] [Related]
4. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract][Full Text] [Related]
5. Mucosa-Associated Microbiota in Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma Differ Similarly Compared With Healthy Controls.
Peter S; Pendergraft A; VanDerPol W; Wilcox CM; Kyanam Kabir Baig KR; Morrow C; Izard J; Mannon PJ
Clin Transl Gastroenterol; 2020 Aug; 11(8):e00199. PubMed ID: 32955191
[TBL] [Abstract][Full Text] [Related]
6. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
[TBL] [Abstract][Full Text] [Related]
7. Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma.
Lv J; Guo L; Liu JJ; Zhao HP; Zhang J; Wang JH
World J Gastroenterol; 2019 May; 25(18):2149-2161. PubMed ID: 31143067
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Helicobacter pylori infection in 160 patients with Barrett's oesophagus or Barrett's adenocarcinoma.
Lord RV; Frommer DJ; Inder S; Tran D; Ward RL
Aust N Z J Surg; 2000 Jan; 70(1):26-33. PubMed ID: 10696939
[TBL] [Abstract][Full Text] [Related]
9. Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens.
Chettouh H; Mowforth O; Galeano-Dalmau N; Bezawada N; Ross-Innes C; MacRae S; Debiram-Beecham I; O'Donovan M; Fitzgerald RC
Gut; 2018 Nov; 67(11):1942-1949. PubMed ID: 29084829
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.
Weston AP; Badr AS; Topalovski M; Cherian R; Dixon A; Hassanein RS
Am J Gastroenterol; 2000 Feb; 95(2):387-94. PubMed ID: 10685740
[TBL] [Abstract][Full Text] [Related]
11. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality?
Blackett KL; Siddhi SS; Cleary S; Steed H; Miller MH; Macfarlane S; Macfarlane GT; Dillon JF
Aliment Pharmacol Ther; 2013 Jun; 37(11):1084-92. PubMed ID: 23600758
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.
Gharahkhani P; Fitzgerald RC; Vaughan TL; Palles C; Gockel I; Tomlinson I; Buas MF; May A; Gerges C; Anders M; Becker J; Kreuser N; Noder T; Venerito M; Veits L; Schmidt T; Manner H; Schmidt C; Hess T; Böhmer AC; Izbicki JR; Hölscher AH; Lang H; Lorenz D; Schumacher B; Hackelsberger A; Mayershofer R; Pech O; Vashist Y; Ott K; Vieth M; Weismüller J; Nöthen MM; ; ; ; Attwood S; Barr H; Chegwidden L; de Caestecker J; Harrison R; Love SB; MacDonald D; Moayyedi P; Prenen H; Watson RGP; Iyer PG; Anderson LA; Bernstein L; Chow WH; Hardie LJ; Lagergren J; Liu G; Risch HA; Wu AH; Ye W; Bird NC; Shaheen NJ; Gammon MD; Corley DA; Caldas C; Moebus S; Knapp M; Peters WHM; Neuhaus H; Rösch T; Ell C; MacGregor S; Pharoah P; Whiteman DC; Jankowski J; Schumacher J
Lancet Oncol; 2016 Oct; 17(10):1363-1373. PubMed ID: 27527254
[TBL] [Abstract][Full Text] [Related]
13. Management of high grade dysplasia in Barrett's oesophagus with underlying oesophageal varices: A retrospective study.
Palmer WC; Di Leo M; Jovani M; Heckman MG; Diehl NN; Iyer PG; Wolfsen HC; Wallace MB
Dig Liver Dis; 2015 Sep; 47(9):763-8. PubMed ID: 26066379
[TBL] [Abstract][Full Text] [Related]
14. Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma.
Lopetuso LR; Severgnini M; Pecere S; Ponziani FR; Boskoski I; Larghi A; Quaranta G; Masucci L; Ianiro G; Camboni T; Gasbarrini A; Costamagna G; Consolandi C; Cammarota G
PLoS One; 2020; 15(5):e0231789. PubMed ID: 32369505
[TBL] [Abstract][Full Text] [Related]
15. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
Incarbone R; Bonavina L; Bassi F; Peracchia A
Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
[TBL] [Abstract][Full Text] [Related]
16. Increased detection rates of Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma.
Hurschler D; Borovicka J; Neuweiler J; Oehlschlegel C; Sagmeister M; Meyenberger C; Schmid U
Swiss Med Wkly; 2003 Sep; 133(37-38):507-14. PubMed ID: 14652799
[TBL] [Abstract][Full Text] [Related]
17. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?
Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T
Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485
[TBL] [Abstract][Full Text] [Related]
18. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
[TBL] [Abstract][Full Text] [Related]
19. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a minimally invasive cell sampling device ('Cytosponge') in the diagnosis of esophageal pathology: a systematic review.
Iqbal U; Siddique O; Ovalle A; Anwar H; Moss SF
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1261-1269. PubMed ID: 30044236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
